Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
OLMA Olema Pharmaceuticals
4.710-0.030-0.63%
Close
01/27 16:00 ET
5.000+0.290+6.16%
Post Mkt Price 01/27 17:51 ET
High
4.990
Open
4.680
Turnover
517.08K
Low
4.462
Pre Close
4.740
Volume
106.45K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Cantor Biotech/biopharma Analysts Hold Analyst/industry Conference Call
SLRX, CNET and WISA Among Mid-day Movers
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersLucid Diagnostics (NASDAQ:LUCD) shares moved upwards by 10.9% to $1.73 during Tuesday's after-market session. The market value of their outstanding shares is at $67.6 million. Nymox Pharmaceuti
Is Olema Pharmaceuticals (NASDAQ:OLMA) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares
BLI, SRGA and UPLD Are Among After Hour Movers
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersShuttle Pharmaceuticals (NASDAQ:SHPH) stock rose 17.5% to $2.08 during Thursday's after-market session. At the close, Shuttle Pharmaceuticals's trading volume reached 565.4K shares. This is 40.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", "Olema Oncology", Nasdaq: OLMA) today announced that Sean Bohen, M.D., President and Chief Executive Officer, w
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Needs To Drive Business Growth Carefully
Critical Survey: Selecta Biosciences (NASDAQ:SELB) Versus Olema Pharmaceuticals (NASDAQ:OLMA)
Selecta Biosciences (NASDAQ:SELB – Get Rating) and Olema Pharmaceuticals (NASDAQ:OLMA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two
Company Overview
More
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
CEO： Dr. Sean Bohen, M.D.,PhD
Market： NASDAQ
Listing Date： 11/19/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet